Marinus Pharmaceuticals 将来の成長
Future 基準チェック /56
Marinus Pharmaceuticalsは、67.6%と34.9%でそれぞれ年率67.6%で利益と収益が成長すると予測される一方、EPSはgrowで72.2%年率。
主要情報
67.6%
収益成長率
72.2%
EPS成長率
Pharmaceuticals 収益成長 | 23.7% |
収益成長率 | 34.9% |
将来の株主資本利益率 | n/a |
アナリストカバレッジ | Good |
最終更新日 | 14 Nov 2024 |
今後の成長に関する最新情報
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 16Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target
May 11Recent updates
A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price
Sep 20Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 16Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target
May 11Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%
Apr 16Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 08Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Dec 22Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?
Sep 22Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S
Jun 12Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically
May 16Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts
Oct 26Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?
Oct 12Marinus Pharmaceuticals: Positive News Flow Of Note
Sep 22Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M
Aug 29Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher
Aug 13Marinus Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy
Jul 28Revisiting Marinus Pharmaceuticals
May 05Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues
Mar 27Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Mar 03Marinus Stock Slides To 18-Month Low, Upcoming PDUFA May Offer Redemption
Feb 28業績と収益の成長予測
日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
---|---|---|---|---|---|
12/31/2026 | 71 | -23 | 89 | 283 | 7 |
12/31/2025 | 51 | -55 | -40 | -40 | 10 |
12/31/2024 | 35 | -116 | -101 | -100 | 9 |
9/30/2024 | 31 | -140 | -116 | -115 | N/A |
6/30/2024 | 30 | -149 | -121 | -120 | N/A |
3/31/2024 | 28 | -145 | -114 | -114 | N/A |
12/31/2023 | 31 | -141 | -118 | -118 | N/A |
9/30/2023 | 31 | -134 | -113 | -113 | N/A |
6/30/2023 | 26 | -29 | -119 | -117 | N/A |
3/31/2023 | 22 | -35 | -128 | -127 | N/A |
12/31/2022 | 25 | -20 | -115 | -113 | N/A |
9/30/2022 | 20 | -14 | -115 | -113 | N/A |
6/30/2022 | 28 | -105 | -80 | -78 | N/A |
3/31/2022 | 28 | -91 | -69 | -67 | N/A |
12/31/2021 | 15 | -99 | -58 | -55 | N/A |
9/30/2021 | 15 | -88 | -52 | -50 | N/A |
6/30/2021 | 5 | -84 | -71 | -70 | N/A |
3/31/2021 | 4 | -76 | -63 | -63 | N/A |
12/31/2020 | 2 | -76 | -61 | -61 | N/A |
9/30/2020 | 0 | -74 | -61 | -61 | N/A |
6/30/2020 | N/A | -72 | -58 | -58 | N/A |
3/31/2020 | N/A | -69 | -51 | -51 | N/A |
12/31/2019 | N/A | -54 | -49 | -49 | N/A |
9/30/2019 | N/A | -49 | -42 | -42 | N/A |
6/30/2019 | N/A | -46 | -37 | -36 | N/A |
3/31/2019 | N/A | -43 | -34 | -33 | N/A |
12/31/2018 | N/A | -37 | -28 | -28 | N/A |
9/30/2018 | N/A | -31 | -23 | -23 | N/A |
6/30/2018 | N/A | -24 | N/A | -19 | N/A |
3/31/2018 | N/A | -19 | N/A | -18 | N/A |
12/31/2017 | N/A | -19 | N/A | -19 | N/A |
9/30/2017 | N/A | -20 | N/A | -20 | N/A |
6/30/2017 | N/A | -22 | N/A | -24 | N/A |
3/31/2017 | N/A | -27 | N/A | -26 | N/A |
12/31/2016 | N/A | -29 | N/A | -25 | N/A |
9/30/2016 | N/A | -30 | N/A | -24 | N/A |
6/30/2016 | N/A | -29 | N/A | -23 | N/A |
3/31/2016 | N/A | -25 | N/A | -22 | N/A |
12/31/2015 | N/A | -25 | N/A | -20 | N/A |
9/30/2015 | N/A | -21 | N/A | -17 | N/A |
6/30/2015 | N/A | -18 | N/A | -14 | N/A |
3/31/2015 | N/A | -17 | N/A | -11 | N/A |
12/31/2014 | N/A | -13 | N/A | -9 | N/A |
9/30/2014 | N/A | -12 | N/A | -10 | N/A |
6/30/2014 | N/A | -12 | N/A | -8 | N/A |
3/31/2014 | N/A | -11 | N/A | -7 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: MRNSは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。
収益対市場: MRNS今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。
高成長収益: MRNS今後 3 年以内に収益を上げることが予想されます。
収益対市場: MRNSの収益 ( 34.9% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。
高い収益成長: MRNSの収益 ( 34.9% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: MRNSの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です